Cargando…
Contribution of NIH funding to new drug approvals 2010–2016
This work examines the contribution of NIH funding to published research associated with 210 new molecular entities (NMEs) approved by the Food and Drug Administration from 2010–2016. We identified >2 million publications in PubMed related to the 210 NMEs (n = 131,092) or their 151 known biologic...
Autores principales: | Galkina Cleary, Ekaterina, Beierlein, Jennifer M., Khanuja, Navleen Surjit, McNamee, Laura M., Ledley, Fred D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878010/ https://www.ncbi.nlm.nih.gov/pubmed/29440428 http://dx.doi.org/10.1073/pnas.1715368115 |
Ejemplares similares
-
NIH funding for patents that contribute to market exclusivity of drugs approved 2010–2019 and the public interest protections of Bayh-Dole
por: Ledley, Fred D., et al.
Publicado: (2023) -
NIH funding for vaccine readiness before the COVID-19 pandemic
por: Kiszewski, Anthony E., et al.
Publicado: (2021) -
Comparing long-term value creation after biotech and non-biotech IPOs, 1997–2016
por: Cleary, Ekaterina Galkina, et al.
Publicado: (2021) -
Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019
por: Galkina Cleary, Ekaterina, et al.
Publicado: (2023) -
As Technologies for Nucleotide Therapeutics Mature, Products Emerge
por: Beierlein, Jennifer M., et al.
Publicado: (2017)